GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » PS Ratio

Pluri (PLUR) PS Ratio : 91.43 (As of May. 15, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Pluri PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pluri's share price is $6.0342. Pluri's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.07. Hence, Pluri's PS Ratio for today is 91.43.

The historical rank and industry rank for Pluri's PS Ratio or its related term are showing as below:

PLUR' s PS Ratio Range Over the Past 10 Years
Min: 20.75   Med: 459.38   Max: 8286.67
Current: 93.44

During the past 13 years, Pluri's highest PS Ratio was 8286.67. The lowest was 20.75. And the median was 459.38.

PLUR's PS Ratio is ranked worse than
84.98% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs PLUR: 93.44

Pluri's Revenue per Sharefor the three months ended in Mar. 2024 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.07.

Warning Sign:

Pluri Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Pluri was -12.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 84.70% per year.

During the past 13 years, Pluri's highest 3-Year average Revenue per Share Growth Rate was 84.70% per year. The lowest was -77.00% per year. And the median was -6.25% per year.

Back to Basics: PS Ratio


Pluri PS Ratio Historical Data

The historical data trend for Pluri's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri PS Ratio Chart

Pluri Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,418.74 7,072.00 - 169.66 101.84

Pluri Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 214.74 101.84 97.96 67.19 -

Competitive Comparison of Pluri's PS Ratio

For the Biotechnology subindustry, Pluri's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's PS Ratio distribution charts can be found below:

* The bar in red indicates where Pluri's PS Ratio falls into.



Pluri PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Pluri's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=6.0342/0.066
=91.43

Pluri's Share Price of today is $6.0342.
Pluri's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Pluri  (NAS:PLUR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Pluri PS Ratio Related Terms

Thank you for viewing the detailed overview of Pluri's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pluri (PLUR) Business Description

Traded in Other Exchanges
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
Executives
Lorne Kenneth Abony director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman officer: Chief Executive Officer 63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership 10 percent owner BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer director 33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun director 9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay officer: Chief Financial Officer ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat director HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram director 24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda officer: Chief Financial Officer MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain director WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi officer: Chief Financial Officer MATAM PARK, BUILDING 05, HAIFA L3 31905

Pluri (PLUR) Headlines

From GuruFocus

Pluri CEO Issues Shareholder Update

By PurpleRose PurpleRose 07-25-2022

Pluri to Present and Participate in Upcoming Conferences

By Value_Insider Value_Insider 10-31-2022